{"id":"W2147486721","doi":"10.1002/cncr.27745","title":"Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Bortezomib; Bevacizumab; Multiple myeloma; Clinical endpoint; Internal medicine; Hazard ratio; Refractory (planetary science); Adverse effect; Placebo; Gastroenterology; Proteasome inhibitor; Phases of clinical research; Progressive disease; Oncology; Surgery; Randomized controlled trial; Confidence interval; Clinical trial; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01046707,0.002243281,0.004155079,0.0005858419,0.0005479552,0.001410704,0.001089284,0.002297344,0.009231525],"category_scores_gemma":[0.007517626,0.0008152906,0.003461846,0.0004456764,0.0009550069,0.001339451,0.0005508793,0.004116303,0.001174929],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009329212,"about_ca_system_score_gemma":0.001919765,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006773394,"about_ca_topic_score_gemma":0.001477772,"domain_scores_codex":[0.9958424,0.002958141,0.0002297379,0.0004191007,0.0003249491,0.0002257054],"domain_scores_gemma":[0.9935902,0.002906591,0.001632083,0.0003432145,0.0003847309,0.001143238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9815381,0.003545347,0.0005035337,0.0003977828,0.001994081,0.00002629231,0.00002572105,0.0002752948,0.00103716,0.00006215196,0.0017816,0.008813003],"study_design_scores_gemma":[0.9544302,0.04018778,0.002411862,0.00004449327,0.001428804,0.00003316653,0.000008471241,0.0002638084,0.000247426,0.0001288849,0.000803349,0.00001178118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9314735,0.02399367,0.002524978,0.004307921,0.001600896,0.01480957,0.01251668,0.0004433006,0.008329607],"genre_scores_gemma":[0.9549673,0.007386997,0.004526102,0.004535737,0.001340055,0.01246575,0.008849762,0.0001296483,0.005798707],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01046707,"threshold_uncertainty_score":0.05535579,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06845420894354572,"score_gpt":0.3886860045544843,"score_spread":0.3202317956109386,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}